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Traumatic brain injury (TBI) poses a major public health 
problem. It is amongst the leading causes of mortality in 
young people in developed countries, and many survivors 
of TBI suffer from persistent disabilities. As a result, there 
remains an unmet clinical need for the development of more 
robust diagnostic and prognostic indicators of TBI. Axonal 
injury is a key driver of the ongoing pathological process 
following TBI, causing chronic neurological deficits and 
disability, and has been the focus of research in this area to 
date. A popular approach has been the investigation of body 
fluid (serum, CSF and saliva) biomarkers to assess axonal 
injury in the acute setting. Biomarkers can be any quantifi-
able product serving as a marker of physiological insult, 
and recent studies have highlighted several substances that 
appear both promising and clinically relevant. However, it is 
likely that eventually the optimal model for assessing axonal 
injury in TBI is likely to involve multi-faceted components, 
including multiple biomarkers and select advanced neuroim-
aging modalities. If successful, early and reliable identifica-
tion of axonal injury post-TBI has the potential to enhance 
current care by increasing speed and accuracy of diagnosis, 
providing prognostic information, allowing patient stratifica-
tion and efficient allocation of rehabilitation services, and 
providing better understanding if the underlying pathology, 
and discovery of potential therapeutic targets.
In this article, we review three studies investigating can-
didate serum biomarkers of TBI, with a focus on their poten-
tial relationship with clinical outcomes within both human 
and animal models.
Increases of plasma levels of glial fibrillary 
acidic protein, tau, and amyloid b 
up to 90 days after traumatic brain injury
Bogoslovsky et al. conducted a study which aimed to iden-
tify the trajectory of three specific serum biomarkers—
tau, glial fibrillary acid protein (GFAP), and amyloid beta 
(AB42)—from the acute–subacute stages after TBI, com-
pared with controls.
Thirty-four patients were identified from a cohort of cases 
recruited to a clinical trial (COBRIT—the Citicoline Brain 
Injury Treatment Trial). Blood samples had already been 
collected from these patients at 24-h, and 30- and 90-day 
post-injury. Age-matched controls were identified from a 
combination of bespoke recruitment (n = 19) and a com-
mercial source (n = 50). High-sensitivity ELISAs, wherein 
investigators were blinded as to assay origins, were con-
ducted to quantify serum biomarker levels. These data were 
then integrated with analysis of admission injury severity, 
Marshall CT grade, duration of post-traumatic amnesia 
(PTA) and clinical outcomes, and Glasgow Outcome Score 
Extended (GOSE).
Plasma levels of GFAP, tau, and AB42 were elevated 
after TBI at all three time points compared to controls. 
Receiver operated characteristic (ROC) analysis revealed 
excellent discrimination between controls and TBI-cases at 
24-h for GFAP and tau (Area under curve 0.94 and 0.90, 
respectively). Serum tau and AB42 remained markedly ele-
vated up to 90-day post-TBI, whereas GFAP levels declined 
rapidly. Marshall CT grade and duration of PTA weakly cor-
related to tau level at 30-day post-TBI; however, there was 
no correlation between GFAP or AB42 and these markers of 
injury severity. There was a weak correlation between day 
30 AB42 and GOSE.
Comment This study adds to existing literature detailing 
the kinetics of serum biomarker kinetics after TBI. Further-
more, serum GFAP levels reliably differentiated TBI patients 
from controls at 24-h post-injury. AB42 and tau increased 
more gradually post-injury, and their elevation is sus-
tained for months post-TBI. Combined with the correlation 
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between AB42 and clinical outcome, the study highlights the 
potential of these biomarkers to act as potential diagnostic or 
prognostic clinical tools in the assessment of TBI patients.
However, the study design may have been optimised 
to assess the utility of biomarkers as a diagnostic tool if a 
cohort of disease control patients had been included in addi-
tion to healthy controls. The study also identified its patient 
cohort from a group recruited to a discontinued randomised 
trial of citicoline in TBI. It is unclear how many of the TBI 
patients were exposed to the drug, which may influence cell 
membrane properties and thus the ability of biomarkers to 
leak into serum post-TBI. Furthermore, gender differences 
in responses to TBI have been reported in the literature, and 
in this study there was a significant discrepancy in gender 
proportions in the patient cohort (85% male) vs the con-
trol group (51% male). Future human studies should aim to 
control for these and other confounding factors, (e.g. pol-
ytrauma, pre-hospital substance misuse, inpatient prescrip-
tion drugs) when investigating the diagnostic and prognostic 
validity of serum biomarkers of TBI.
Bogoslovsky T et al. (2017) Journal of Neurotrauma 34 
(1):66–73.
Correlation of mechanical impact responses 
and biomarker levels: a new model 
for biomarker evaluation in TBI
This paper reports a study investigating rat head kinematics 
during head impacts, providing data supporting the validity 
of an animal model of TBI. Levels of biomarkers were meas-
ured in both CSF and serum (GFAP, IL-6, tau and AB42) 
after controlled mechanical head injuries were administered 
to anaesthetized rats. The authors hypothesised that this 
panel of biomarkers correlate to measured mechanical head 
injury impacts and, therefore, may be helpful in determining 
TBI severity.
The study utilises the Marmarou impact model, described 
in detail in the study methods. In brief, a 450 g weight was 
released onto anaesthetized Sprauge–Dawley rats from 1.25, 
1.75 and 2.25 m to simulate varying severity of TBI, respec-
tively. Impact kinetics such as power and acceleration were 
recorded electronically, and post-impact time to self-right 
was measured as a marker of behavioural response to the 
injury. Biomarkers were collected from CSF and the serum 
24-h post-injury.
Biomechanical and behavioural responses differed sig-
nificantly between all impact groups versus controls, and 
between the 1.75- and 2.25-m impact groups (p < 0.05). 
There were statistically significant raised levels of NF-H, 
GFAP and IL-6 in 2.25-m group compared to controls, and 
all other impact groups. There was no difference in AB42 
levels in any of the impact groups compared to controls. 
Pearson’s correlation analysis showed pNF-H and GFAP lev-
els in CSF and serum had positive correlation with impact 
power and time to surface right (p < 0.01). No significant 
correlation was noted between post-injury IL-6 or AB42 and 
injury severity or time to surface right.
Comments TBI assessment and study in humans is often 
influenced by multiple confounding factors, e.g. polytrauma, 
varied mechanism of injury, and substance misuse. This 
study reports the biomechanical impact kinetics associated 
with one animal model of TBI, which holds the advantage 
of providing a method of controlling for many of the con-
founders associated with human studies of TBI. The authors 
also purport that levels of NF-H and GFAP had positive cor-
relation with head kinematics and, therefore, that these two 
substances are potential biomarkers for TBI. The model used 
in this study is thus purported to hold a unique ability to aid 
in elucidating the relationship between biomarker levels and 
severity of the mechanical trauma to the brain.
However, the model utilised restricts biomarker analysis 
to a single time-point post-injury and, therefore, biomarker 
kinetic profiles cannot be assessed unless modifications 
to the methods for serum and CSF collection were made. 
Indeed, levels of AB42 are thought to rise at 3–5 days post-
injury at the earliest, potentially explaining the absence of 
elevation of this biomarker in the present study. The influ-
ences of the inhaled anaesthetic upon blood–brain barrier 
function and ergo biomarker levels must also be acknowl-
edged as a potential confounding factor. Revisiting the 
authors’ hypothesis, this work identifies that part of the 
panel of biomarkers described (GFAP and NF-H in par-
ticular) correlates with measured mechanical head injury 
impacts in this animal model of TBI and, therefore, they may 
have utility in determining TBI severity, if this relationship 
can be studied and verified in carefully controlled human 
studies of brain injury.
Li Y et al. (2015) J Neurol Sci. 359(1–2):280–6.
Comparative assessment of the prognostic 
value of biomarkers in traumatic brain injury 
reveals an independent role for serum levels 
of neurofilament‑light
Neurofilament-light (NF-L) is a neuron-specific protein, 
wherein it functions as a component of the axonal cytoskel-
eton. In this study, serum and CSF NF-L levels were meas-
ured after TBI in humans, alongside analysis of neuroradio-
logical injury scores (primarily the Stockholm CT Severity 
score), initial injury severity, and clinical outcomes. A total 
of 182 patients suffering TBI admitted to a single neuro-
intensive unit were included. Serum NF-L levels were 
acquired, together with S100B and neuron-specific enolase 
(NSE). CSF-NF-L was measured in a sub-cohort (n = 84) 
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who underwent ventriculostomies as part of their TBI care. 
Outcome was assessed 6–12 months after injury using the 
Glasgow Outcome Score (1–5).
Both serum and CSF levels of NF-L demonstrated ele-
vated during the first 15 days after trauma. There was a cor-
relation between serum and CSF NF-L levels. There was 
no correlation between CSF or serum NF-L and MRI or 
CT imaging parameters of injury severity (Stockholm CT 
severity score and degree of midline shift on MRI). There 
was, however, a statistically significant correlation between 
NF-L levels and clinical outcome (p = 0.0056). Furthermore, 
in a multivariate analysis, when compared to the correla-
tion of NSE and S100B with several measures of clinical 
outcomes, the authors concluded that a significantly better 
model predicting TBI severity was obtained when these bio-
markers were combined (p = 0.006). These results indicate 
that both serum S100B and NF-L are potential predictors of 
TBI outcome. The investigators thus purport that this study 
demonstrates that serum NF-L correlates with TBI outcome, 
even if used in models combined with other biomarkers less 
specific to neurons, such as S100B. This suggests that NF-L 
may hold an independent contribution to the prediction of 
outcomes after TBI, perhaps by reflecting key pathophysi-
ological processes post-injury. These processes may not be 
possible to monitor via conventional neuroradiological bio-
markers. This may explain the lack of correlation between 
NF-L and neuroimaging severity scores identified in this 
study.
Comments: Whilst numerous biomarkers have been 
shown to relate to TBI, many of these are expressed in mul-
tiple tissues and, therefore, the presence of polytrauma may 
be a significant confounding factor in their utility as diag-
nostic or prognostic tools in clinical practice. There was a 
statistically significant correlation between serum NF-L and 
clinical outcome after TBI identified in the present study. It 
is argued that this neuronal protein may, therefore, be a more 
specific indicator of axonal injury than other biomarkers. 
This patient cohort primarily consisted of severe–moderate 
TBI patients, (92%) and there was significant variability in 
the time points at which neuroimaging was performed, and 
when CSF or serum was sampled for each patient; a more 
regimented sampling regime would have been be desirable 
to facilitate more controlled analysis and interpretation of 
data. Whilst the 3-week half-life outcome was also assessed 
at a single time-point (6–12 months) post-TBI, despite the 
fact that many patients continue to improve up to and beyond 
12 months post-injury. More regular patient follow-up, and 
more robust measures of neurological function (neuropsy-
chological/cognitive testing) would be desirable in future 
work assessing clinical outcomes after TBI in relation to 
biomarkers.
No correlation between NF-L and conventional CT or 
MRI imaging was identified in this study. This may reflect 
the fact that diffuse axonal injury is difficult to assess using 
conventional neuroimaging techniques. Future studies, aim-
ing to elucidate potential relationships between biomarkers 
and neuroimaging after TBI may need to consider utilising 
novel advanced imaging techniques, such as diffusion tensor 
imaging and tractography, to validate the presence of axonal 
injury within patient cohorts.
Al-Nimer F et al. (2015) PLoS ONE 10(7):e0132177
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